SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude prices climb amid reported Middle East shipping and energy-infrastructure attacks, fueling concerns about supply disruptions. Traders are divided between expecting the supply-risk rally to continue and anticipating a pullback if tensions ease; some also caution that the expiring WTI contract can distort comparisons with the next contract.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves sharp selloff is being tied to HSBCs bearish outlook, which flagged debt costs, financing needs and the risk that AI-compute demand may slow. Traders are split: bears see leverage as a threat to the neocloud business model, while bulls cite AI demand and the companys backlog; Goldmans upgrade and ARK buying have not resolved the concerns.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A tech-led rebound after the recent selloff, ahead of major megacap earnings, is driving QQQ discussion. Traders are divided over whether it marks a durable recovery or a relief rally that could fade, with AI investment and debt concerns and surging oil prices adding to caution.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares have slid to post-IPO lows amid concern over insider selling and successive lockup share releases, with traders also pointing to a TD Cowen price-target cut and questions about growth, scaling, and reliance on OpenAI. The discussion is sharply divided between calls for more downside and buyers arguing the selloff is overdone and the AI-chip technology has long-term potential.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale shares are under pressure after UBS downgraded the stock, citing long commercialization timelines and limited firm customer commitments, with uncertainty around the proposed TVA deployment adding to execution concerns. Traders are split between viewing the selloff as an overreaction and seeing it as confirmation of risks facing NuScale and the broader nuclear sector.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospaces third-quarter earnings beat and raised 2026 guidance are driving attention, with traders also citing stronger orders. Many view the report as bullish, while others are cautious about whether the stock can hold its post-earnings strength amid muted or weakening price action.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is drawing attention after reporting a better-than-expected third quarter and raising its automotive free-cash-flow outlook while narrowing full-year guidance, prompting a broadly positive earnings reaction. Some traders remain cautious about cost pressures and scrutiny of the 6.2L engine recall remedy.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Hot inflation readings and elevated yields have intensified concerns about Fed tightening, weighing on rate-sensitive small caps and keeping IWM near key support after a sharp pullback. Traders are split between expecting further downside and looking for an oversold bounce as yields ease and money rotates toward smaller companies.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

A sharp selloff in AI infrastructure and neocloud stocks, fueled by concerns about whether massive buildout spending can earn adequate returns and by CoreWeaves debt risks, has dominated discussion around Nebius. Traders are divided over whether the pullback and subsequent bounce are an opportunity, with some arguing Nebius is better positioned than peers and others worried that sector-wide financing concerns will keep pressuring shares.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrop Grummans Q3 results and higher full-year guidance are drawing attention, with traders also citing a record backlog and stronger B-21 and Sentinel activity. Despite the upbeat report, shares remain under pressure as investors weigh margin and cash-flow concerns against the improved outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ABVX Stock Clocks Best Day In 11 Months On Analyst Upgrades After Fresh Data Eases Drug Safety Concerns 

Equity

Wedbush, BTIG and Jefferies weighed in on ABVX on Tuesday after the company unveiled updated safety and efficacy data from an obefazimod study. 


ABVX Stock Rockets 28% After Abivax Eases Drug Safety Concerns With Fresh Clinical Data

Abivax said the findings strengthen the overall case for obefazimod and reinforce its favorable benefit-risk profile.


ABVX Stock Clocks Worst Day Ever On Malignancy Signal For Drug: ‘Pharma Bro’ Says ‘GLPs Are Doing Fine’ After Similar Fears  

Shares of ABVX closed down 44% on Tuesday, clocking its worst day ever, on reports of a number of non-melanoma skin cancers and other malignancies observed in its ulcerative colitis trial. 


ABVX Tanks 30% After-Hours Despite 51% Remission In Ulcerative Colitis Trial — Rare Cancer Concerns Hit Sentiment

The company dismissed the cancers observed in the trial as rare, occurring primarily in older patients, and largely unrelated to treatment. 


Goldman Sachs ETF Trust - Goldman Sachs Hedge IND VIP ETF

Neutral Sentiment

<ul class="summary-bullets"><li>BTIG raised its price target on Abivax to $175 from $150 and maintained a Buy rating.</li><li>Wedbush said that it remains concerned about how the FDA will view cancer risk and the potential for a Black Box warning.</li><li>Abivax also announced on Tuesday the launch of an underwritten public offering of around $600 million in American Depositary Shares.</li></ul><p>Shares of Abivax (ABVX) clocked their best day in about 11 months on Tuesday on the heels of multiple price target revisions and updated safety and efficacy data from a study that addressed prior investor worries about cancer risk tied to its ulcerative colitis candidate, obefazimod.</p><p>ABVX stock closed 39% higher and slipped marginally by 0.15% after-hours, at the time of writing, after the company announced a $600-million public offering.</p><h2 class="st-heading-2">Trial Data</h2><p>Abivax <a href="https://stocktwits.com/news-articles/markets/equity/abvx-stock-rockets-after-abivax-eases-drug-safety-concerns-with-fresh-clinical-data/cZ19pPuR7L8">released</a> the updated study data after-hours on Monday. The data showed malignancy rates, including non-melanoma skin cancers, remained consistent with background rates in ulcerative colitis patients. Four NMSC cases were reported in Part 2 of the trial—two per dose arm—mostly in patients with pre-existing risk factors, while two additional non-NMSC malignancies in the 50 mg group were deemed unrelated to the drug.</p><p>Abivax said the data reinforce obefazimod’s favorable benefit-risk profile. More than one-third of patients in the higher-dose group achieved clinical remission and mucosal healing at week 44. The company plans to submit a U.S. FDA new drug application in the fourth quarter.</p><h2 class="st-heading-2">Wall Street Weighs In</h2><p>BTIG raised its price target on Abivax to $175 from $150 and maintained a Buy rating. The analyst said the latest update provided additional safety data confirming a sufficiently clean safety profile for obefazimod. BTIG’s new price target represents a potential upside of about 31% from the stock’s closing price on Tuesday.</p><p>Wedbush analyst David Nierengarten raised the firm’s price target to $110 from $90 but kept a Neutral rating. While the pooled safety data appeared in line with background malignancy rates in ulcerative colitis, Wedbush remains concerned about how the FDA will view cancer risk and the potential for a Black Box warning. Nierengarten’s new price target assumed a potential downside of about 17% from the stock’s closing price.</p><p>Jefferies upgraded Abivax to Buy from Hold and lifted its price target to $158 from $108, representing a potential upside of nearly 19% from the stock’s last close. The firm said the Part 2 update “appropriately addresses the key overhang facing the stock” and that management did a good job addressing investor concerns with the presentation of the safety data. Jefferies also noted that the efficacy profile continues to strengthen with additional data.</p><h2 class="st-heading-2">Abivax Launches $600-Million Public Offering</h2><p>Separately, Abivax announced on Tuesday the launch of an underwritten public offering of around $600 million in American Depositary Shares. The company intends to use the net proceeds for U.S. commercialization expenses of obefazimod, clinical development in ulcerative colitis and Crohn’s disease, and general corporate purposes.</p><h2 class="st-heading-2">How Did ABVX Retail Traders React?</h2><p>On Stocktwits, retail sentiment around ABVX stayed within the ‘bullish’ territory over the past 24 hours, while message volume jumped from ‘normal’ to ‘high’ levels.</p><p>A Stocktwits user opined that the capital raise is to convince interested partners that the company can also move forward solo.</p><p><stembedurl>https://www.stocktwits.com/Miles223/message/657970692</stembedurl></p><p>Another user echoed the sentiment, positioning the capital raise as proof that the company received “lowball M&amp;A offers.”</p><p><stembedurl>https://www.stocktwits.com/p3akyblinder/message/657971234</stembedurl></p><p>A third user voiced hopes for an imminent near-term buyout for the company.</p><p><stembedurl>https://www.stocktwits.com/MZ2X/message/657969299</stembedurl></p><p><a href="https://stocktwits.com/symbol/ABVX">ABVX stock</a> has traded nearly flat year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/uncy-stock-clocks-worst-day-in-year-analysts-keep-buy-ratings-despite-5-12-month-delay-in-drug-approval/cZ1QMSoR70o">UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Abivax logo is seen displayed on a smartphone screen

Wedbush, BTIG and Jefferies weighed in on ABVX on Tuesday after the company unveiled updated safety and efficacy data from an obefazimod study. 

Abivax - ADR

iShares Biotechnology ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$163.98
Prev Close	$163.02
Open	$164.26
Dividend Yield	N/A
50-Day Moving Average	$171.59
Beta	N/A
Avg. Volume	8,927.19
PE Ratio	N/A

52-Week High	$192.13
52-Week Low	$138.73
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

GVIP Fundamentals